When C4 Therapeutics, Inc. (CCCC) reports fourth-quarter and full-year 2023 results, investors will primarily focus on pipeline updates.The company has a decent track record of beating on earnings in three of the trailing four quarters and missing in one, delivering an average surprise of 5.04%. In the last reported quarter, it delivered an earnings surprise of 15.38%.Factors to NoteC4 Therapeutics is a clinical-stage biopharmaceutical company, advancing targeted protein degradation science to develop a new ...

Wall Street expects a year-over-year increase in earnings on higher revenues when C4 Therapeutics, Inc. (CCCC) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss ...

Table of Contents Table of Contents NOTE REGARDING COMPANY REFERENCES Table of Contents Table of Contents C4 Therapeutics, Inc. See accompanying notes to unaudited condensed consolidated financial statements. Table of Contents | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------|--------------------------------|----------------------|-------|-------|----------------------------------------|-------------- ...

Table of Contents Table of Contents C4 Therapeutics, Inc. | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------|-----------------|------------------|-------|------------------------------|-------|---------------------------------------------------|---------------------|---------------|------------------------------| | | Common \nShares | Stock \nAmount | | Additional \nPaid-In Capital | | Accumulated Other \nComprehensive Income (Loss) | ...

48 Table of Contents patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that our product candidates or use of our technologies infringes upon these patents. If we are found by a court of competent jurisdiction to infringe a third party's intellectual property rights, we could be required to obtain a license from the applicable third-party intellectual property holder to continue developing and marketing our product candidates, products, an ...

0- -- Patient 1 - Patient 2 -25 - Patient 3 cent Change e -50 -75 -100- 20 0 10 15 Day 15 AUC0-24h (hr*ng/mL) — Simulated IKZF3 Degradation 50 µg © 2023 C4 Therapeutics, Inc. Potential for CFT7455 to replace other IKFZ1/3 degraders and become a backbone therapy CFT7455 © 2023 C4 Therapeutics, Inc. No approved therapies specifically for synovial sarcoma • Potent | --- | --- | --- | --- | |--------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | Protein degraded. | | | | ...

Table of Contents Washington, D.C. 20549 The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The NASDAQ Stock Market on June 30, 2022, was $201,260,869. The number of shares of Registrant's Common Stock outstanding as of February 15, 2023 was 49,050,851. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant's definitive proxy statement for its 2022 Annual Meeting of Stockholders t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to _________________ ...

© 2022 C4 Therapeutics, Inc. | Delivering on the Promise of Targeted Protein Degradation August, 2022 Forward-looking Statements and Intellectual Property Forward-looking Statements The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "pr ...

Table of Contents Title of each classTrading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSIT ...